“McKesson Ventures is excited to invest in Clinical ink, a market leader in clinical trial enablement technology. Clinical ink’s innovative eSource solutions are particularly well-positioned as the industry shifts to more decentralized trials and remote monitoring,” said Dave Schulte, senior vice president and managing director of McKesson Ventures. 

Clinical trial sponsors can now choose deployment modalities to suit their protocols and patients, rather than having technology drive the selection. Despite the higher complexity this flexibility might suggest, ePRO+ still supports the rapid system implementation Clinical ink is known for, with study builds now less than 30 days, including translations. 

“As the eSource pioneers with tens of thousands of site-user interactions behind us, we know our solutions must be adaptable to patients’ and sites’ day-to-day realities,” said Clinical ink CEO Ed Seguine. “A unified, flexible, patient-centric solution helps patients consistently contribute the data that sponsors need, giving confidence in the data integrity, whatever the trial design. McKesson Ventures’ investment further validates the need for, and opportunity represented by, these technologies.” 

Lunexis ePRO+ is part of an eSource ecosystem that simplifies sponsors’ and CROs’ real-time data collection workflows, enabling study teams to confidently make critical study decisions. Sponsors stand to gain higher quality data as more actively engaged patients and sites enter information more efficiently according to protocol. 

Lunexis ePRO+ does more than just simplify data collection; TransPerfect Translations has partnered with Clinical ink to completely reimagine and simplify the complex translation process. “The novel way translations are handled in Lunexis ePRO+ alleviates inefficiencies in the feedback process and condenses the typical ePRO translation workflow and timeline, which can be considerable,” said Alexandra Crane, senior director, global head of COA solutions & implementation at TransPerfect. 

These advancements for streamlining and optimizing operational execution anticipate the rapidly changing needs of the clinical research industry. Mixed-modality capabilities, associated changes to the clinician-reported outcomes (ClinRO) feature set, and time-saving, unified authoring allow for extreme flexibility and are ideal for a wide variety of physical, virtual, and hybrid clinical trials. By harnessing this vision and years of experience, this launch builds even more momentum and positions Clinical ink to continue in its role as industry leader well into the future. 

Learn more about Clinical ink’s Lunexis ePRO+: Visit clinicalink.com/technology/ecoa/. 

About Clinical ink
Clinical ink, a global clinical technology company, offers data certainty from source to submission. Our Lunexis eSource clinical technology and configurable direct data capture, eCOA, ePRO, and eConsent modules — a suite of solutions for capturing and integrating electronic data from sites, clinicians, and patients at its source — naturally enhance your clinical trial workflow by reducing manual labor, providing anytime, anywhere data access, and saving resources as your trials progress. Visit clinicalink.com. 

About McKesson Ventures
McKesson Ventures is a strategic venture firm backed by McKesson Corporation focusing on early and growth stage health technology and healthcare services companies. McKesson Ventures targets companies that both catalyze and benefit from the key changes taking place in the U.S. healthcare landscape. McKesson Corporation is a healthcare services and information solutions company dedicated to making the business of healthcare run better. Visit www.mckessonventures.com to learn more. 

The post McKesson Ventures Invests as Clinical ink Debuts Lunexis ePRO+ Solution Mixed Modalities Allow Users to Switch Between Smartphones, Tablets, and Web Any Time appeared first on Clinical ink.

The post Clinical Ink to Accelerate Innovation and Growth with Major Investment By NovaQuest Private Equity appeared first on Clinical ink.

“Advancements in data collection technology will enable clinical trial sponsors to improve protocol execution and ultimately shorten the clinical trial lifecycle” said E. Wayne Holden, PhD, president and CEO of RTI International. “Clinical ink’s technology aimed at providing real-time access to high-quality study data is complementary to RTI’s scientific leadership in the areas of patient reported outcomes and large-scale data collection used in a variety of research studies. Advancing new clinical trial technology is well aligned with RTI’s mission to improve the human condition by turning knowledge into practice.”

Since 2007, Clinical ink has focused on being the pioneering provider of eSource and patient engagement technologies for clinical trials. Its SureSource Platform is used in data capture, ePRO, eCOA and remote monitoring. Founded in Winston-Salem, NC, Clinical ink is committed to reducing the cost and complexity for clinical research for sites, sponsors and patients.

“We are excited to be a co-investment partner with NovaQuest and extend our healthcare and life sciences expertise to Clinical ink,” said Matt Jenkins, vice president and head of corporate development at RTI. “This deal fits well with our philosophy of investing alongside strong management teams and investment partners in high growth markets with a connection to our core research work and mission.”

“RTI’s global reach, scale, and depth of scientific expertise is wonderful to have as a co-investor,” said Ed Seguine, CEO of Clinical ink.  “Having support from NovaQuest and RTI, who are both deeply experienced in the life sciences and clinical research sectors, is ideal for us as we commence the next stage of growth for Clinical ink.”

About RTI International

RTI International is an independent, nonprofit research institute dedicated to improving the human condition. Clients rely on us to answer questions that demand an objective and multidisciplinary approach—one that integrates expertise across the social and laboratory sciences, engineering, and international development. We believe in the promise of science, and we are inspired every day to deliver on that promise for the good of people, communities, and businesses around the world.  For more information, visit www.rti.org.

About NovaQuest Capital Management, L.L.C.

NovaQuest Capital Management is a leading investor in life sciences and healthcare through its BioPharma and Private Equity strategies. NovaQuest was formed in 2000 with the vision of building an investment platform to provide strategic capital to life sciences and healthcare companies. Today, NovaQuest Capital Management manages over $1.8 billion through its BioPharma and Private Equity strategies. The investment team consists of highly seasoned operational and investment professionals with significant investment experience and deep life science and healthcare expertise. Furthermore, NovaQuest benefits from an extensive network of industry experts and relationships that assist in identifying, analyzing and growing NovaQuest portfolio companies and investments. For more information, please visit www.novaquest.com.

About Clinical ink

Clinical ink is a global clinical trial technology company that is transforming the clinical trial experience. Founded in 2007, the Company’s proven and future-built eSource platform, which includes solutions for EDC replacement, eCOA, ePRO and more, accelerates time to value while delivering scientific results that matter. With offices in Winston-Salem, NC, and Philadelphia, PA, Clinical ink is advancing the business model responsible for bringing new treatments to market. Visit clinicalink.com.

Media Contact: Jessica Romero | 336.728.6541 | jessica.romero@clinicalink.com

The post RTI International Announces Co-Investment with NovaQuest Capital Management in Research Technology Company Clinical ink appeared first on Clinical ink.